Spots Global Cancer Trial Database for pathologic stage iiid cutaneous melanoma ajcc v8

Every month we try and update this database with for pathologic stage iiid cutaneous melanoma ajcc v8 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors	NCT05039801	Advanced Endome... Advanced Head a... Advanced Malign... Advanced Melano... Advanced Ovaria... Chondrosarcoma Clinical Stage ... Clinical Stage ... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Recurrent Ovari... Refractory Endo... Refractory Head... Refractory Mela... Refractory Ovar... Refractory Ovar... Stage III Ovari... Stage III Uteri... Stage IIIA Ovar... Stage IIIA Uter... Stage IIIA1 Ova... Stage IIIA2 Ova... Stage IIIB Ovar... Stage IIIB Uter... Stage IIIC Ovar... Stage IIIC Uter... Stage IIIC1 Ute... Stage IIIC2 Ute... Stage IV Ovaria... Stage IV Uterin... Stage IVA Ovari... Stage IVA Uteri... Stage IVB Ovari... Stage IVB Uteri...	Bevacizumab Glutaminase-1 I... Paclitaxel Capivasertib	18 Years -	M.D. Anderson Cancer Center
Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma	NCT04310397	Pathologic Stag... Pathologic Stag... Pathologic Stag...	Dabrafenib Spartalizumab Therapeutic Con... Trametinib	18 Years -	M.D. Anderson Cancer Center
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies	NCT02419495	Advanced Malign... Clinical Stage ... Clinical Stage ... Fallopian Tube ... Metastatic Lung... Metastatic Mali... Metastatic Mela... Metastatic Rena... Ovarian Carcino... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Primary Periton... Stage III Lung ... Stage III Renal... Stage IIIA Lung... Stage IIIB Lung... Stage IIIC Lung... Stage IV Lung C... Stage IV Renal ... Stage IVA Lung ... Stage IVB Lung ... Triple-Negative... Unresectable Lu... Unresectable Me... Unresectable Re...	Capecitabine Carboplatin Cyclophosphamid... Doxorubicin Eribulin Fluorouracil Ipilimumab Irinotecan Hydr... Leucovorin Calc... Nivolumab Olaparib Oxaliplatin Paclitaxel Pembrolizumab Pemetrexed Selinexor Topotecan	18 Years -	M.D. Anderson Cancer Center
Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma	NCT03865212	Clinical Stage ... Clinical Stage ... Metastatic Chor... Metastatic Mela... Metastatic Muco... Metastatic Uvea... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Unresectable Me...	Recombinant Ves...	18 Years -	Mayo Clinic
Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement	NCT04221438	Melanoma of Unk... Metastatic Mali... Pathologic Stag... Pathologic Stag... Pathologic Stag... Recurrent Cutan...	Binimetinib Computed Tomogr... Conventional Su... Encorafenib Fluorothymidine... Positron Emissi...	18 Years -	Eastern Cooperative Oncology Group
Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement	NCT04221438	Melanoma of Unk... Metastatic Mali... Pathologic Stag... Pathologic Stag... Pathologic Stag... Recurrent Cutan...	Binimetinib Computed Tomogr... Conventional Su... Encorafenib Fluorothymidine... Positron Emissi...	18 Years -	Eastern Cooperative Oncology Group
Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors	NCT04990726	Clinical Stage ... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Melanoma, Stage... Melanoma Stage ...	Assessment Biospecimen Col... Quality-of-Life... Questionnaire A...	18 Years -	M.D. Anderson Cancer Center
Bone Loss in Melanoma Survivors Receiving Immunotherapy	NCT04516122	Clinical Stage ... Clinical Stage ... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag...	Biospecimen Col... Dual X-ray Abso...	40 Years -	M.D. Anderson Cancer Center
Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma	NCT04940299	Clinical Stage ... Clinical Stage ... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Malignant Solid... Metastatic Blad... Metastatic Blad... Metastatic Lung... Metastatic Mela... Metastatic Rena... Metastatic Uret... Metastatic Uret... Metastatic Uret... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Stage III Bladd... Stage III Lung ... Stage III Renal... Stage III Urete... Stage III Ureth... Stage IIIA Blad... Stage IIIA Lung... Stage IIIB Blad... Stage IIIB Lung... Stage IIIC Lung... Stage IV Bladde... Stage IV Lung C... Stage IV Renal ... Stage IV Ureter... Stage IV Urethr... Stage IVA Lung ... Stage IVB Lung ... Unresectable Me...	Ipilimumab Nivolumab Tocilizumab	18 Years -	M.D. Anderson Cancer Center
Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma	NCT04375527	Clinical Stage ... Clinical Stage ... Locally Advance... Metastatic Cuta... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Unresectable Cu...	Binimetinib Nivolumab Questionnaire A...	18 Years -	Jonsson Comprehensive Cancer Center
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors	NCT05039801	Advanced Endome... Advanced Head a... Advanced Malign... Advanced Melano... Advanced Ovaria... Chondrosarcoma Clinical Stage ... Clinical Stage ... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Recurrent Ovari... Refractory Endo... Refractory Head... Refractory Mela... Refractory Ovar... Refractory Ovar... Stage III Ovari... Stage III Uteri... Stage IIIA Ovar... Stage IIIA Uter... Stage IIIA1 Ova... Stage IIIA2 Ova... Stage IIIB Ovar... Stage IIIB Uter... Stage IIIC Ovar... Stage IIIC Uter... Stage IIIC1 Ute... Stage IIIC2 Ute... Stage IV Ovaria... Stage IV Uterin... Stage IVA Ovari... Stage IVA Uteri... Stage IVB Ovari... Stage IVB Uteri...	Bevacizumab Glutaminase-1 I... Paclitaxel Capivasertib	18 Years -	M.D. Anderson Cancer Center
Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma	NCT03554083	Clinical Stage ... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag...	Atezolizumab Cobimetinib Tiragolumab Vemurafenib	18 Years -	Mayo Clinic
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer	NCT03819296	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Colitis Lung Non-Small ... Malignant Genit... Malignant Solid... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Stage 0 Lung Ca... Stage I Lung Ca... Stage IA1 Lung ... Stage IA2 Lung ... Stage IA3 Lung ... Stage IB Lung C... Stage II Lung C... Stage IIA Lung ... Stage IIB Lung ... Stage III Lung ... Stage IIIA Lung... Stage IIIB Lung... Stage IIIC Lung... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ...	Best Practice Biospecimen Col... Endoscopic Proc... Fecal Microbiot... Infliximab Laboratory Biom... Prednisone Vedolizumab	18 Years -	M.D. Anderson Cancer Center
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies	NCT04902040	Advanced Bladde... Advanced Lung N... Advanced Malign... Advanced Melano... Advanced Merkel... Advanced Renal ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Stage III Bladd... Stage III Lung ... Stage III Renal... Stage IIIA Blad... Stage IIIA Lung... Stage IIIB Blad... Stage IIIB Lung... Stage IIIC Lung... Stage IV Bladde... Stage IV Lung C... Stage IV Renal ... Stage IVA Bladd... Stage IVA Lung ... Stage IVB Bladd... Stage IVB Lung ...	Atezolizumab Avelumab Durvalumab Nivolumab Pembrolizumab Plinabulin Radiation Thera...	18 Years -	M.D. Anderson Cancer Center
A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy in Patients With Operable Melanoma	NCT04708418	Clinical Stage ... Melanoma of Unk... Pathologic Stag... Pathologic Stag... Pathologic Stag... Recurrent Cutan...	Biopsy Biospecimen Col... Computed Tomogr... Pembrolizumab Positron Emissi... Surgical Proced... VLP-encapsulate...	18 Years -	National Cancer Institute (NCI)
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies	NCT04902040	Advanced Bladde... Advanced Lung N... Advanced Malign... Advanced Melano... Advanced Merkel... Advanced Renal ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Stage III Bladd... Stage III Lung ... Stage III Renal... Stage IIIA Blad... Stage IIIA Lung... Stage IIIB Blad... Stage IIIB Lung... Stage IIIC Lung... Stage IV Bladde... Stage IV Lung C... Stage IV Renal ... Stage IVA Bladd... Stage IVA Lung ... Stage IVB Bladd... Stage IVB Lung ...	Atezolizumab Avelumab Durvalumab Nivolumab Pembrolizumab Plinabulin Radiation Thera...	18 Years -	M.D. Anderson Cancer Center
Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients	NCT05176470	Locally Advance... Pathologic Stag... Pathologic Stag... Pathologic Stag... Stage IV Melano...	Cyclophosphamid... Fludarabine Lifileucel Pembrolizumab Therapeutic Con...	18 Years - 75 Years	Ohio State University Comprehensive Cancer Center
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer	NCT03819296	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Colitis Lung Non-Small ... Malignant Genit... Malignant Solid... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Stage 0 Lung Ca... Stage I Lung Ca... Stage IA1 Lung ... Stage IA2 Lung ... Stage IA3 Lung ... Stage IB Lung C... Stage II Lung C... Stage IIA Lung ... Stage IIB Lung ... Stage III Lung ... Stage IIIA Lung... Stage IIIB Lung... Stage IIIC Lung... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ...	Best Practice Biospecimen Col... Endoscopic Proc... Fecal Microbiot... Infliximab Laboratory Biom... Prednisone Vedolizumab	18 Years -	M.D. Anderson Cancer Center
Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers	NCT03816332	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Metastatic Basa... Metastatic Mela... Metastatic Merk... Metastatic Skin... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Unresectable Ba... Unresectable Me... Unresectable Me...	Ipilimumab Nivolumab Prednisone Tacrolimus	18 Years -	National Cancer Institute (NCI)
Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial	NCT04462406	Advanced Melano... Clinical Stage ... Clinical Stage ... Melanoma of Unk... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Unresectable Ac... Unresectable Me... Unresectable Mu...	Ipilimumab Nivolumab Patient Observa... Pembrolizumab	18 Years -	Eastern Cooperative Oncology Group
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors	NCT05039801	Advanced Endome... Advanced Head a... Advanced Malign... Advanced Melano... Advanced Ovaria... Chondrosarcoma Clinical Stage ... Clinical Stage ... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Recurrent Ovari... Refractory Endo... Refractory Head... Refractory Mela... Refractory Ovar... Refractory Ovar... Stage III Ovari... Stage III Uteri... Stage IIIA Ovar... Stage IIIA Uter... Stage IIIA1 Ova... Stage IIIA2 Ova... Stage IIIB Ovar... Stage IIIB Uter... Stage IIIC Ovar... Stage IIIC Uter... Stage IIIC1 Ute... Stage IIIC2 Ute... Stage IV Ovaria... Stage IV Uterin... Stage IVA Ovari... Stage IVA Uteri... Stage IVB Ovari... Stage IVB Uteri...	Bevacizumab Glutaminase-1 I... Paclitaxel Capivasertib	18 Years -	M.D. Anderson Cancer Center
Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial	NCT04462406	Advanced Melano... Clinical Stage ... Clinical Stage ... Melanoma of Unk... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Unresectable Ac... Unresectable Me... Unresectable Mu...	Ipilimumab Nivolumab Patient Observa... Pembrolizumab	18 Years -	Eastern Cooperative Oncology Group
Bone Loss in Melanoma Survivors Receiving Immunotherapy	NCT04516122	Clinical Stage ... Clinical Stage ... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag...	Biospecimen Col... Dual X-ray Abso...	40 Years -	M.D. Anderson Cancer Center
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies	NCT02419495	Advanced Malign... Clinical Stage ... Clinical Stage ... Fallopian Tube ... Metastatic Lung... Metastatic Mali... Metastatic Mela... Metastatic Rena... Ovarian Carcino... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Primary Periton... Stage III Lung ... Stage III Renal... Stage IIIA Lung... Stage IIIB Lung... Stage IIIC Lung... Stage IV Lung C... Stage IV Renal ... Stage IVA Lung ... Stage IVB Lung ... Triple-Negative... Unresectable Lu... Unresectable Me... Unresectable Re...	Capecitabine Carboplatin Cyclophosphamid... Doxorubicin Eribulin Fluorouracil Ipilimumab Irinotecan Hydr... Leucovorin Calc... Nivolumab Olaparib Oxaliplatin Paclitaxel Pembrolizumab Pemetrexed Selinexor Topotecan	18 Years -	M.D. Anderson Cancer Center

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: